Markets:

Overview

News

Currencies

International

Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.280 UNCHANGED

Last Price Updated: 8:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc. Common Shares

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Psychedelic Stock Gainers And Losers From April 26, 2022 ↗

April 26, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.61% at $0.29

Via Benzinga

Psychedelic Drug Patenting: Still Only Scratching The Surface ↗

April 26, 2022

Psychedelic drug R&D remains in its infancy, with dozens of psychedelics and several

Via Talk Markets

ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today ↗

April 25, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.97% at $4.97

Via Benzinga

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved ↗

April 25, 2022

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami...

Via Benzinga

Missed The Benzinga Psychedelics Capital Conference? Check Out Full Recording And Exclusive Coverage ↗

April 25, 2022

Via Benzinga

Cybin Presents "Why Cybin Is Investing So Heavily On Developing Novel Psychedelic Molecules" At The Psychedelic Capital Conference ↗

April 25, 2022

Photo by Presetbase Lightroom Presets on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today ↗

April 22, 2022

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 3.49% at $0.87

Via Benzinga

Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp ↗

April 22, 2022

Three weeks after announcing the results of its preclinical trials for CYB003, Cybin (NYSE:CYBN) made public a partnership with Clinilabs Drug Development Corporation to take the proprietary drug to...

Via Benzinga

Cybin (NYSE American: CYBN) (NEO: CYBN) To Present At KCSA Psychedelics Conference ↗

April 22, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today ↗

April 21, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 20.83% at $0.29

Via Benzinga

Psychedelic Stock Gainers And Losers From April 20, 2022 ↗

April 20, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.69% at $0.16 LOSERS:

Via Benzinga

EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space ↗

April 19, 2022

Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock. In the psychedelic space, catalysts could be...

Via Benzinga

Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today ↗

April 19, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.57% at $0.33

Via Benzinga

EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics ↗

April 19, 2022

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you.

Via Benzinga

Psychedelic Stock Gainers And Losers From April 18, 2022 ↗

April 18, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.66% at $0.28

Via Benzinga

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release ↗

April 18, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Psychedelic Stock Gainers And Losers From April 14, 2022 ↗

April 14, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.50% at $5.32

Via Benzinga

Psychedelic Stock Gainers And Losers From April 13, 2022 ↗

April 13, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.41% at $0.24

Via Benzinga

Cybin's (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study ↗

April 13, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Cybin's CYB0004 Shows Positive Preclinical Results Over Traditional Psychedelics ↗

April 13, 2022

CYB004 is one of Cybin’s (NYSE: CYBN) proprietary second-generation psychedelics, developed to treat depression, anxiety, and ...

Via Benzinga

Psychedelic Stock Gainers And Losers From April 11, 2022 ↗

April 11, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.52% at $0.17

Via Benzinga

Performance Comparisons Of The 5 Cannabis Sector Categories ↗

April 10, 2022

Here is a summary of how each of the 5 categories in the cannabis sector performed over four time periods, to highlight the different category trends that are underway.

Via Talk Markets

Revive Therapeutics, Cybin Among Top Psychedelic Movers Of Today ↗

April 08, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.54% at $0.16

Via Benzinga

WIPO Publishes Cybin's Patent Application For Inhaled Psychedelics Therapies ↗

April 08, 2022

Cybin Inc. (NYSE: CYBN) announced that the World Intellectual Property Organization (WIPO) published an international patent ...

Via Benzinga

Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position Of Psychedelic Programs ↗

April 08, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today ↗

April 07, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.48% at $0.14

Via Benzinga

Cybi (NEO: CYBN) (NYSE American: CYBN) To Participate In Benzinga Psychedelics Conference ↗

April 07, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Intelgenx Technologies, Field Trip Health Among Top Psychedelic Movers Of Today ↗

April 06, 2022

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 4.78% at $19.73 LOSERS:

Via Benzinga

A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers ↗

April 06, 2022

From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE: CYBN) CEO, Doug Drysdale has certainly had an ...

Via Benzinga

Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More! ↗

April 06, 2022

It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Cybin Inc. Common Shares (NY:CYBN)

Headline News about Cybin Inc. Common Shares

Starting at $3.75/week.

Subscribe Today